Endeavour Establishes Largest Medtech Fund in Europe at EUR 250m

ST PETER PORT, Guernsey - Thursday, March 31st 2016 [ME NewsWire]

    Endeavour Medtech Growth (EMG) Fund final close at EUR 250m (USD 275m)
    EMG is the largest fund in Europe dedicated to medtech
    Fund oversubscribed – significantly exceeds EUR 150m target
    Fund to allocate between EUR 10m and EUR 20m per investment

(BUSINESS WIRE)-- Endeavour Vision today announced that the Endeavour Medtech Growth LP (EMG) fund has held its final close at EUR 250m (USD 275m) in committed capital. Largely oversubscribed, the fund reached its hard cap and closed well above its EUR 150m target due to considerable interest from new institutional investors. At EUR 250m, EMG is the largest fund dedicated to medtech in Europe and one of the largest pure medtech funds worldwide.

EMG is targeting high potential European and US companies in the medical device and digital health sectors, which have innovative solutions that have already gained regulatory approval and are starting to generate commercial traction. The Fund will support the worldwide development of companies changing the standard of care in various therapeutic indications, with a typical allocation between EUR 10m and EUR 20m per investment.

The medtech market was estimated at USD 369b worldwide in 20151 and it is evolving at a rapid pace, creating new opportunities for investors. The world’s population is aging, requiring more and safer treatments. At the same time, the healthcare systems have limited financial resources and thus require less expensive treatments and increased prevention. Innovative medtech companies are using new technologies to address these challenges and provide new ways to treat diseases and improve the standard of care.

Bernard Vogel, Managing Partner of Endeavour Vision Ltd, advisor to the Fund, said: “The medtech sector is evolving rapidly and presents very clear opportunities as we see life sciences and information technology converging in an incredible fashion. This successful fund raising is a strong endorsement of the team’s solid track record and capabilities, as well as its strategy.”

EMG has already closed four investments: Gynesonics, a company developing and commercialising an innovative and minimally invasive treatment for uterine fibroids, and ReShape Medical, a company which has developed an FDA-approved intra-gastric balloon for minimally invasive weight loss. The two additional transactions will be announced in the coming weeks.

An advisor to the Fund, Damien Tappy, President and Managing Partner of Endeavour Vision Ltd, commented “Endeavour features a unique team with unrivalled experience globally, which brings tremendous added value to innovative medtech companies. The fund is targeting highly differentiated innovations that have the potential to drastically change the standard of care for millions of patients, with a commitment to help those technologies become the most successful high-growth companies in the world.”

Sven Lingjaerde, Managing Partner of Endeavour Vision Ltd, added “With the combination of recent major advances in both healthcare and digital technology information, medicine will experience unprecedented changes that will revolutionize the current healthcare paradigm. Thanks to our long and successful experience in technology and life sciences, we are uniquely positioned to select the right opportunities in this fast growing environment.”

About Endeavour Vision Ltd

Endeavour Vision is an internationally recognized investor in the healthcare and technology sectors. The team, which combines successful investment professionals and world-class industry veterans, has executed more than 65 investments within its focus verticals.

With the closing of the Endeavour Medtech Growth Fund, the firm is advising the largest investment vehicle in Europe and dedicated to, helping medical technology companies in Europe and the US to accelerate their global growth and market leadership.

For more information about Endeavour and its portfolio, please visit www.endeavourvision.com.

1 Source: Evaluategroup



View source version on businesswire.com: http://www.businesswire.com/news/home/20160322005669/en/

Contacts

Weber Shandwick Switzerland

Laetitia Tettamanti

+41 22 879 85 02

endeavour@webershandwick.com









Permalink: http://me-newswire.net/news/17463/en

WISeKey to List on the SIX Swiss Stock Exchange on March 31, 2016

WISeKey International Holding Ltd (“WIHN”) announces successful exchange offer for WISeKey SA shares – 90.9% tendered

ZUG, Switzerland - Thursday, March 31st 2016 [ME NewsWire]

Listing and first trading day of WIHN Class B Shares on the SIX Swiss Exchange on March 31, 2016



(BUSINESS WIRE)-- WISeKey International Holding Ltd (“WIHN”) announced today that it has successfully completed all steps to list its registered shares, nominal value CHF 0.05 (“Class B Shares”), on the SIX Swiss Exchange on March 31, 2016:

    90.9% of WISeKey SA's shareholders, the main operating company of the WISeKey group, have tendered their WISeKey SA shares into WIHN's share exchange offer (the "Exchange Offer") in exchange for new Class B Shares, thus establishing WIHN as the holding company of the WISeKey group. WIHN will take the steps necessary to acquire full ownership of WISeKey SA, by entering into further private transactions or through a follow-up squeeze-out merger;
    WIHN has acquired in a share-for-share transaction WISeTrust SA, the holder of the U.S. cryptographic root key IP rights;
    As from the date of listing the WIHN's Class B Shares on the SIX Swiss Exchange, WIHN has access to a share subscription facility entered into with institutional investor Global Emerging Markets (“GEM”), under which GEM has committed to subscribe, at the option of the company, to newly issued Class B Shares for a value of up to CHF 60 million; and,
    SIX Exchange Regulation has approved the listing of Class B Shares in accordance with the International Reporting Standard, with the first trading day taking place on March 31, 2016. The indicative reference share price submitted by WIHN's management to SIX Swiss Exchange is CHF 15, translating to a market capitalization based on the listed Class B Shares of approximately CHF 220 million and an equity value of all issued Class A and Class B Shares of approximately CHF 340 million. The indicative reference price is based on WIHN's own assessment of the Class B Share fair equity value, third party valuations from renowned investment banks and prior equity rounds.

As a result, Class B Shares will be listed and for the first time traded on the SIX Swiss Exchange on March 31, 2016 (ISIN: CH0314029270 / Valor: 31402927 / Ticker: WIHN). Class B Shares represent approximately 65% of WIHN’s capital and approximately 27% of the WIHN's voting rights. WIHN's Class A Shares, nominal value CHF 0.01 each ("Class A Shares"), conferring a voting right privilege on its holders, are held by a core group of shareholders and will not be listed and tradable on the SIX Swiss Exchange.

WISeKey is a leading Swiss cybersecurity company and selected as a World Economic Forum Global Growth Company. WISeKey has raised more than CHF 120 million since its incorporation, is deploying large scale Internet of Things (“IoT”) digital identity ecosystems and has become a pioneer of the 4th Industrial Revolution movement launched this year at the World Economic Forum in Davos. WISeKey’s Swiss based Cryptographic Root of Trust (“RoT”) integrates wearable technology with secure authentication and identification, in both physical and virtual environments, and empowers IoT and wearable devices to become secure transactional devices. WISeKey has patented this process in Switzerland, Australia, Canada and the USA and it is currently used by many IoT providers.

Carlos Moreira, Founder, Chairman and CEO of WIHN stated: “We are thrilled by the outstanding support of WISeKey SA's shareholders for our share exchange offer and are very excited that WIHN will now become the first publicly listed Root of Trust based cybersecurity company on the SIX Swiss Exchange. This will create great momentum for us to progress our revenue and profitability growth path going forward and for Switzerland to enhance its position as a cybersecurity hub globally."

ACXIT Capital Partners Ltd acts as sole financial advisor and listing agent to WISeKey International Holding Ltd. Homburger Ltd acts as legal counsel to WISeKey International Holding Ltd.

About WISeKey:

WISeKey is one of the world’s fastest-growing cybersecurity companies and a global growth company partner of the World Economic Forum. WISeKey provides specialized technologies for data protection, effective authentication and identification and authentication of people and objects to ensure secured communications and transactions without compromising trust. WISeKey runs its own Root of Trust cybersecurity platform and identity-based data security solutions for international organizations, governments, enterprises, and financial institutions spanning 102 countries. WISeKey is headquartered in Geneva with operations in Vietnam and the US. It intends to aggressively build out its US operations with hubs in California and Maryland. WISeKey has already embedded root of trust based security in over 2.6 billion browsers, sensors and wearables in addition to offering the industry's trusted suite of IoT security products using the fact that authentication is becoming an increasingly important cybersecurity IoT consideration.

Disclaimer:

This communication expressly or implicitly contains certain forward-looking statements concerning WISeKey International Holding Ltd and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of WISeKey International Holding Ltd to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. WISeKey International Holding Ltd is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and it does not constitute an offering prospectus within the meaning of article 652a or article 1156 of the Swiss Code of Obligations or a listing prospectus within the meaning of the listing rules of the SIX Swiss Exchange. Investors must rely on their own evaluation of WISeKey and its securities, including the merits and risks involved. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of WISeKey.    

View this news release online at:
http://www.businesswire.com/news/home/20160330005626/en

Contacts

For further information, please contact:

WISeKey International Holding Ltd:

Carlos Moreira, +41 22 594 3000

Chairman & CEO

cmoreira@wisekey.com









Permalink: http://www.me-newswire.net/news/17467/en

New Clinical Study Reports Relationship Between Masimo’s Oxygen Reserve Index (ORI™) and Arterial Partial Pressure of Oxygen During Surgery

NEUCHATEL, Switzerland - Thursday, March 31st 2016 [ME NewsWire]

(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) announced today that a new retrospective study reports the relationship between Masimo’s Oxygen Reserve Index (ORI™) and arterial partial pressure of oxygen (PaO2) during surgery. The study suggests that ORI may provide an advanced indication of impending desaturation in adults undergoing surgery based on trends in the relationship between ORI and PaO2.1

ORI, Masimo’s 11th rainbow® parameter2, which is available outside of the United States, is a relative index of the PaO2 operating in the range of 100 to 200 mm Hg. ORI can provide a calculated oxygen reserve index that may add to information from pulse oximetry when oxygen saturation (SpO2) is >98%. ORI is intended to supplement, not replace, SpO2 monitoring and PaO2 measurements.

In the study, published in the journal Anesthesia & Analgesia and conducted at Loma Linda University, Dr. Applegate and colleagues studied 106 patients in which arterial catheterization and intraoperative arterial blood gas analysis were planned during surgery. Multiwavelength Pulse CO-oximetry data from multiple sensors on each patient were continuously collected (Masimo Radical-7® with Root®). A retrospective analysis was then conducted to evaluate the ORI to PaO2 relationship.

Regression analysis showed a positive ORI to PaO2 relationship for PaO2 values up to 240 mm Hg (r2 = 0.536), but not for PaO2 over 240 mm Hg (r2 = 0.0016). Measured PaO2 was ≥100 mm Hg for all ORI values over 0.24, and when ORI was higher than 0.55, the measured PaO2 was ≥150 mm Hg in 96.6% of samples.

The investigators concluded, “This study suggests that intraoperative ORI can distinguish PaO2 between 100 and 150 mm Hg when SpO2 is >98%. Decreases in ORI to near 0.24 may provide advance indication of falling PaO2 when SpO2 is still >98% and above the PaO2 level at which SaO2 [arterial oxygen saturation] declines rapidly. Usefulness of ORI >0.24 to distinguish PaO2 ≥100 mm Hg and ORI >0.55 to distinguish PaO2 ≥150 mm Hg should be tested prospectively in a range of clinical settings.” Additionally, the investigators noted that “the clinical utility of interventions based on continuous ORI monitoring should also be studied prospectively,” and that other clinical or feasibility limitations may not have been identified. The authors also noted that the study was limited by a small number of subjects and samples with PaO2 values <100 mm Hg, and that the study results did not apply to intensive care settings.

The Loma Linda University School of Medicine, Department of Anesthesiology received a grant from Masimo to support the data collection for this study.

Radical-7 with Root has a CE Mark with the ORI parameter. ORI has not received FDA 510(k) clearance and is not available for sale in the United States.

@MasimoInnovates | #Masimo

1. Applegate RL 2nd, Dorotta IL, Wells B, Juma D, Applegate PM. The Relationship Between Oxygen Reserve Index and Arterial Partial Pressure of Oxygen During Surgery. Anesth Analg. 2016 Mar 22. [Epub ahead of print] PubMed PMID: 27007078.

2. The 11 rainbow® parameters include: 1) oxygen saturation (SpO2); 2) Pulse rate; 3) Perfusion index (PI); 4) Pleth Variability Index (PVI®); 5) Respiration Rate from the pleth (RRp®); 6) Total hemoglobin (SpHb®); 7) Oxygen Content (SpOC™); 8) Carboxyhemoglobin (SpCO®); 9) Methemoglobin (SpMet®); 10) Fractional oxygen saturation (SpfO2®); 11) Oxygen Reserve Index (ORI™)

About Masimo

Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and more recently, Pleth Variability Index (PVI®) and Oxygen Reserve Index (ORI™), in addition to SpO2, pulse rate, and perfusion index (PI). In 2014, Masimo introduced Root®, an intuitive patient monitoring and connectivity platform with the Masimo Open Connect (MOC-9) interface. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7™ wearable patient monitor and the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at www.masimo.com. All published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo’s Oxygen Reserve Index (ORI™). These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo’s Oxygen Reserve Index (ORI™), contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions with comparable accuracy and unique advantages, including: immediate and continuous results that enable earlier treatment without causing invasive trauma in all patients and in every clinical situation; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=51310436&lang=en

Contacts

Masimo

Irene Paigah

858-859-7001

irenep@masimo.com









Permalink: http://www.me-newswire.net/news/17465/en

Gore Launches Unique Biomaterial for Complex Ventral Hernia Repair

Gore to launch its new hybrid device, GORE® SYNECOR Biomaterial, at the 17th Annual Hernia Repair Conference in Washington, D.C.

FLAGSTAFF, Ariz. - Thursday, March 31st 2016 [ME NewsWire]

(BUSINESS WIRE)-- W. L. Gore & Associates, Inc. (Gore) today announced the launch of GORE® SYNECOR Biomaterial, a unique hybrid device for hernia repair, at the 17th Annual Hernia Repair Conference held March 30-April 2, 2016 in Washington, D.C. During the conference, Gore will kick off the Technology Experiential Center (TEC) Tour, a new kind of interactive experience where participants will learn about the science behind the new material using hands-on stations.

Hernia repair has traditionally required a surgeon to choose between a permanent material for a durable, single-stage repair, or absorbable, non-permanent materials where there are factors that may require a different approach. GORE SYNECOR Biomaterial, which received 510(k) clearance from the US Food and Drug Administration in December 2015, is comprised of three materials, including:

    GORE® BIO-A® Web, a tissue-building scaffold providing rapid vascularization and ingrowth for complex repairs
    A macroporous knit of dense, monofilament polytetrafluoroethylene (PTFE) fibers that provides strength and may reduce the risk of harboring bacteria due to the solid fiber;
    Non-porous PGA/TMC* film that minimizes tissue attachment to the material at the visceral side.

The Gore TEC Tour, a new addition to the AHS annual meeting, will showcase the new biomaterial through the use of interactive stations. Standing out from previous exhibits, the TEC Tour will allow attendees in interactive groups to have discussions and engage with high-level scientific data on the product.

“The advancements in technology over the past few years have provided physicians with an overwhelming number of options when it comes to hernia repair,” said Ron Anderson, General Surgical Products Business Unit Leader. “With the TEC Tour, we are able to discuss the science of the material and pre-clinical testing which offers a deeper level of understanding to help them find the best fit for their practice and patients.”

Gore is actively participating in a Clinical Quality Improvement (CQI) project to procure real world feedback from surgeons and patients about GORE SYNECOR Biomaterial. The project is following a diverse collection of metrics including demographics, pre-, peri-, and post-operative health details, short- and long-term follow up, and costs. The CQI paradigm empowers surgeons and hospitals to efficiently respond to the data findings in real time to improve patient care. For more information on GORE SYNECOR Biomaterial, please visit www.goremedical.com/synecor.

*Polyglycolic acid/trimethylene carbonate

ABOUT US

At Gore Medical, we have provided creative therapeutic solutions to complex medical problems for 40 years. During that time, 40 million innovative Gore Medical Devices have been implanted, saving and improving the quality of lives worldwide. Our extensive family of products includes vascular grafts, endovascular and interventional devices, surgical meshes for hernia and soft tissue reconstruction, staple line reinforcement materials, and sutures for use in vascular, cardiac, and general surgery. We are one of a select few companies to appear on all of the U.S. “100 Best Companies to Work For” lists since the rankings debuted in 1984. For more information, visit www.goremedical.com.

GORE®, BIO-A®, SYNECOR and designs are trademarks of W. L. Gore & Associates.
© 2016 W. L. Gore & Associates, Inc.    

Contacts

Chempetitive Group for W. L. Gore & Associates

Andrea Vuturo

GoreMedical@Chempetitive.com









Permalink: http://me-newswire.net/news/17466/en

RMB Capital Adds Egor Rybakov to Asset Management Team

Industry Veteran Expands Firm’s International Investment Capabilities

CHICAGO - Thursday, March 31st 2016 [ME NewsWire]

(BUSINESS WIRE)-- Chicago-based RMB Capital (“RMB”), an independent financial services firm with more than $4.3 billion in assets under management, announced today that Egor Rybakov, CFA, has joined RMB Asset Management as a senior vice president and portfolio manager. Rybakov brings to RMB the investment process he has honed for the past two decades—screening the universe of international equities to uncover mispriced quality companies expected to create long-term value. With the addition of Rybakov, RMB will ultimately be able to offer a variety of new international and global strategies—the first being a concentrated portfolio of non-U.S. companies across the market-cap spectrum.

“Bringing Egor on board is an exciting and meaningful development,” said Chris Graff, partner and director of RMB Asset Management. “His research experience, fundamental approach, and focused investment process further expand our firm’s stock-picking capabilities. We now cover the globe.”

Adds Rybakov, “I’m very happy to be joining a dynamic and growing investment group whose approach and philosophy are so closely aligned with mine. Throughout my career, I have focused on discovering mispriced quality companies with durable operations, strong financials, and prudent management teams. Such businesses typically outperform over the long term. My disciplined and time-tested investment process balances pursuit for future value creation with downside protection, offering opportunities for savvy investors to gain exposure to international markets in a prudent manner.”

Prior to joining RMB, Rybakov was senior vice president and portfolio manager at Keeley Asset Management’s global equities practice. Previously, he held international equity portfolio management and research positions at a number of firms, including ENR Investments, Principal Global Investors/EDGE AM, affiliates of Nuveen Investments – Tradewinds Global Investors & SBAM, as well as Thornburg Investment Management. Rybakov holds a bachelor’s degree in economics and management from the Moscow State University (MGU) and an MBA with concentrations in finance and accounting from The University of Illinois at Chicago. He is based in Newport Beach, Calif., where RMB has established a satellite office.

ABOUT RMB ASSET MANAGEMENT

For both individual and institutional investors, RMB Asset Management offers fixed income, equity, and alternative investment strategies run by highly experienced portfolio managers. Underpinning the team’s long-term investment approach is a deep commitment to fundamental research, concentration within portfolios, and risk management.

ABOUT RMB CAPITAL

RMB Capital is an independent, diversified financial services firm. Its businesses include wealth management, asset management, and retirement plan consulting. RMB is headquartered in Chicago with offices in Denver, Jackson Hole, Wyo., and Washington, D.C., as well as several satellite locations. To learn more about RMB Capital, visit www.rmbcap.com.

Contacts

RMB Capital

Media Contact:

Greenhouse Partners

Shawn Malayter, 872-267-2636

Senior Associate

smalayter@greenhousepartners.com



or

RMB Contact:

Kate Demet, 312-784-3203

S.V.P, Director of Marketing & Communications

kdemet@rmbcap.com







Permalink: http://me-newswire.net/news/17457/en

MATRIXX Software Selected by SMART Communications, Attracts Strategic Funding From PLDT

MOUNTAIN VIEW, Calif. - Wednesday, March 30th 2016 [ME NewsWire]

(BUSINESS WIRE)-- MATRIXX Software today announced that SMART Communications, a wholly-owned subsidiary of the Philippine Long Distance Telephone Company (PLDT), has selected MATRIXX Software’s real-time Digital Commerce platform for its mobile business. Subsequently, PLDT has invested in MATRIXX through its investment arm, PLDT Capital.

SMART Communications, the country’s largest mobile network, is deploying the MATRIXX platform to deliver an array of lifestyle services and content that can be individually purchased and customized. SMART’s customers will have the freedom to manage their mobile account usage and spend, tailor services and choose ‘sachet-size’ packages based on their preferences and budgets.

MATRIXX provides a real-time Digital Commerce platform for creating and monetizing content and services. SMART Communications chose MATRIXX because they needed a real-time, customer-centric platform that could jump-start entry into the digital market without a lengthy IT project. MATRIXX installed and integrated the solution within weeks, allowing rapid time-to-market for future service propositions that will capture wallet-share and customer loyalty in a dynamic, fast-paced market.

Winston Damarillo, PLDT Chief Strategy Advisor and PLDT Capital Co-Managing Director said, “Evolution of the telco into a Digital Service Provider requires viewing the customer through a different lens, in order to identify new ways of serving them. We’re transforming the customer experience, and we chose MATRIXX Software because its technology and performance is unmatched, and they are able to help drive the PLDT Group’s digital vision more rapidly than anyone else.”

Dave Labuda, Founder, CEO and CTO, MATRIXX Software, said, “The PLDT Group continues our model of prestigious companies that are investors as well as customers. They are genuinely changing the game in Asia when it comes to digital service innovation, and we’re excited to help deliver outstanding experiences to customers of its wireless service provider, SMART Communications.”

The PLDT group has nearly 70 million wireless subscribers and SMART recently won Best Mobile Operator of the year at the World Communications Awards for the second year running.

To learn more about MATRIXX Software, please visit www.matrixx.com.

About MATRIXX Software

MATRIXX Software is Powering the FutureTM for market-leading Digital Service Providers (DSPs) worldwide.

MATRIXX Software has developed a unique real-time Digital Commerce platform, an alternative to traditional business support systems (BSS), which enables telecom service providers to profit and innovate as they transition to Digital.

Follow MATRIXX Software online:

Website: www.matrixx.com

Vimeo: www.vimeo.com/user17468378

LinkedIn: www.linkedin.com/company/586602

Twitter: www.twitter.com/matrixx_sw

About PLDT

PLDT is the leading telecommunications service provider in the Philippines. Through its principal business groups – fixed line, wireless and others – PLDT offers a wide range of telecommunications services across the Philippines’ most extensive fiber optic backbone and fixed line and cellular networks.

PLDT is listed on the Philippine Stock Exchange (PSE:TEL) and its American Depositary Shares are listed on the New York Stock Exchange (NYSE:PHI). PLDT has one of the largest market capitalizations among Philippine-listed companies. For more information, visit pldt.com.

About SMART Communications

Smart Communications, Inc. (Smart) is the Philippines' leading wireless services provider with 67 million subscribers to date. Smart has built a reputation for innovation, having introduced world-first wireless offerings such as Smart Money, Smart Load and Smart Padala. Smart offers 3G, HSPA+, and LTE services, while its satellite service Smart Link provides communications to the global maritime industry. Smart Broadband, Inc., a wholly-owned subsidiary, offers a wireless broadband service, Smart Broadband, with 2.9 million subscribers.

Smart is a wholly owned subsidiary of the Philippines' leading telecommunications carrier, the Philippine Long Distance Telephone Company. For more information, visit http://www.smart.com.ph.    

Contacts

Babel PR for MATRIXX Software

+44 (0)20 7199 3974

matrixx@babelpr.com



MATRIXX Software

Simon Marshall, +1 307-439-9000

Senior Manager, Marketing and PR

simon.marshall@matrixx.com



PLDT and SMART Communications

Ramon R. Isberto, +63 2 5113101

PLDT Group Spokesperson

Fax No.: +63 2 5113100

RRIsberto@smart.com.ph





Permalink: http://me-newswire.net/news/17449/en

Al Nuaimi and a US Official Review Child Protection Efforts

ABU DHABI, United Arab Emirates - Monday, March 28th 2016 [ME NewsWire]

Major General Dr. Nasser Lakhrebani Al Nuaimi, Secretary General of the Office of HH Deputy Prime Minister and Minister of Interior and Chairman of the Higher Committee for Child Protection at the Ministry of Interior, met Susan Jacobs, Special Advisor for Children’s Issues at the US Department of State.

Al Nuaimi stressed the keenness of the UAE, and its international cooperation in child protection, by adopting the best international police, technological, and procedural practices. He pointed to the role and efforts of the Ministry of Interior in this field, as well as following up on relevant initiatives and projects, which make the UAE a cultural beacon for excellence in child protection, and achieve the government’s vision in this regard.

For her part, Jacobs praised the UAE’s efforts in child protection, and its international role and initiatives, which are considered a role model in this field.

For more information about:

The Ministry of Interior, please click HERE

Abu Dhabi Police, please click HERE

Follow us and check our Social Media feeds on: YouTube, Facebook, Google +, Instagram and Twitter                                                  

The Arabic-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the Arabic-language text, which is the only version of the text intended to have legal effect.

Contacts

The UAE Minister of Interior's General Secretariat, Tactical Affairs and Security Media Department

Abu Dhabi Police GHQ - Security Media

Chris Cron +971-(0)-50-666-4891

E-mail: cron.media@hotmail.com









Permalink: http://www.me-newswire.net/news/17437/en